Langerhans Cell Histiocytosis

Demographics

Pathogenesis

Modern Classification (Histiocyte Society):

1. Single-System LCH:

   • Single-site (solitary eosinophilic granuloma)
   • Multiple-site (polyostotic, pulmonary)

2. Multisystem LCH:

   • Without risk organ involvement
   • With risk organ involvement (liver, spleen, bone marrow, lung)

Skeletal Manifestations

Systemic Manifestations (Multisystem Disease)

Risk Stratification

Treatment by Disease Extent

Surgical Considerations

Complications

Prognosis

The topic lists "neurocognitive dysfunction", cerebellar involvement, white-matter changes and cerebellar atrophy as complications, and names "neurodegenerative LCH" in its own Controversies section - but never develops this distinct, feared entity, which is a favourite "late-effects" viva.

• What it is. Neurodegenerative LCH (LCH-ND) is a progressive, non-mass CNS syndrome that can appear months to many years after the systemic disease has apparently resolved, and is a leading cause of long-term morbidity in survivors. It is distinct from a space-occupying CNS LCH lesion - there is no tumour to resect.
• Who is at risk. The strongest associations are craniofacial/"CNS-risk" lesions (orbit, mastoid, temporal, sphenoid, maxilla/zygoma), diabetes insipidus, multisystem disease, and BRAF V600E positivity - the same lesions that predict diabetes insipidus predict LCH-ND, and the two often coexist as part of the pituitary-hypothalamic/CNS-risk picture.
• How it presents and looks. Insidious cerebellar signs (ataxia, dysarthria, tremor, dysmetria), pyramidal signs, behavioural/learning decline and eventually cognitive impairment. MRI shows symmetrical T2/FLAIR high signal in the dentate nuclei/cerebellar white matter and basal ganglia, sometimes with cerebellar atrophy - changes that can precede symptoms, so at-risk children are surveilled with MRI.
• Why it matters / management. It is thought to be driven by MAPK-activated myeloid cells seeding the CNS (BRAF V600E has been found in the marrow/blood of affected patients), i.e. a neuro-inflammatory/degenerative process rather than direct tumour. Treatment is difficult and not standardised - options include chemotherapy (cytarabine), and increasingly MAPK-pathway (BRAF/MEK) inhibitors, with the hope (unproven) that early targeted therapy may prevent or halt progression. Established neurodegeneration is often irreversible, which is why recognition and surveillance matter.

The topic repeatedly flags pulmonary LCH - "usually older children/adults", "strongly smoking-associated", "distinct natural history", with its own line in the guidelines table - but never develops it, and it is examined as a discrete entity quite unlike the paediatric bone disease.

• A different disease in adults. Isolated pulmonary LCH (PLCH) is largely a disease of young-to-middle-aged adult smokers (typically 20-40 years, roughly equal sex incidence). Unlike multisystem childhood LCH it is often a reactive, polyclonal response to cigarette smoke in many cases (though clonal BRAF V600E-positive forms also occur), which is why it behaves differently.
• Presentation. Cough and dyspnoea, or an incidental finding; a classic acute presentation is a spontaneous pneumothorax (from cyst rupture), which can be recurrent. Constitutional symptoms and extrapulmonary disease are usually absent in the isolated pulmonary form.
• Imaging. HRCT is characteristic: combined nodules and thin-walled cysts with an UPPER- and MID-zone predominance and sparing of the costophrenic angles/lung bases - the reverse of the basal predominance of many other cystic/fibrotic lung diseases. The nodules cavitate into cysts over time.
• Management - stop smoking first. Smoking cessation is first-line and can stabilise or regress disease; it is the single most important intervention. Systemic therapy (e.g. cladribine, or MAPK-directed therapy in clonal disease) is reserved for progressive disease, and lung transplantation for end-stage fibrosis (with a risk of recurrence, especially if smoking resumes). Recurrent pneumothorax may need pleurodesis.

Global Epidemiology

• Incidence approximately 4-9 per million children per year; rarer in adults (1-2 per million)
• Peak 1-3 years for multisystem disease; 5-10 years for single-system bone disease
• Slight male predominance (around 1.2-2:1); reported across all populations worldwide
• Bone is the most common organ involved overall (around 80% of paediatric cases)
• Pulmonary LCH in adults is strongly smoking-associated and follows a distinct natural history

Side-by-Side Guidance

Registry & Trial Networks

• Outcome data are driven by international cooperative trials (LCH-I, LCH-II, LCH-III, LCH-IV) rather than implant/arthroplasty registries
• The Histiocyte Society coordinates global protocol enrolment; regional groups (e.g. NACHO in North America, national paediatric oncology groups in Europe) feed shared datasets
• BRAF/MAPK genotyping is increasingly captured prospectively to stratify targeted-therapy use

High- vs Limited-Resource Practice

• High-resource: routine BRAF/MAP2K1 genotyping, PET-CT staging, access to BRAF/MEK inhibitors and cladribine/cytarabine salvage, long-term endocrine/neurocognitive surveillance
• Limited-resource: diagnosis may rest on morphology plus CD1a/S100 where Langerin and molecular testing are unavailable; skeletal survey substitutes for PET-CT; vinblastine + prednisone remains the affordable, effective backbone; targeted agents often inaccessible
• Universal principles: confirm tissue diagnosis, stage for risk organs, avoid radiotherapy in children, and screen lifelong for diabetes insipidus

• Reactive vs neoplastic: the discovery of clonal MAPK mutations (BRAF V600E, MAP2K1) reframed LCH as an inflammatory myeloid neoplasm, yet the prominent inflammatory infiltrate keeps the "neoplasia vs immune dysregulation" debate alive.
• Optimal duration of targeted therapy: BRAF/MEK inhibitors produce rapid responses but disease frequently rebounds on cessation, and the ideal duration, role of combination with chemotherapy, and long-term toxicity in children remain undefined.
• Vertebra plana management: the balance between observation, intralesional steroid and bracing is not standardised; most lesions reconstitute, but predicting the minority that deform is imprecise.
• Neurodegenerative LCH: progressive cerebellar/brainstem neurodegeneration can appear years after apparent cure; its pathogenesis, screening interval, and whether early MAPK-directed therapy prevents it are unresolved.
• Role of PET-CT vs skeletal survey: PET-CT is more sensitive for occult and extraskeletal disease, but cost, radiation and access limit universal use, so staging strategy varies by setting.

Langerhans cell histiocytosis (LCH) is a clonal proliferation of CD1a+ and Langerin+ dendritic cells with a spectrum ranging from solitary eosinophilic granuloma to disseminated multisystem disease (Letterer-Siwe). It predominantly affects children aged 5-10 years with male predominance (2:1), with the skull (50%) and femur (20%) being the most common skeletal sites. Characteristic findings include "punched-out" lytic skull lesions, vertebra plana in the spine, and histology showing Langerhans cells with coffee-bean nuclei and Birbeck granules. BRAF V600E mutation is present in 50-60% and is a therapeutic target. Treatment ranges from observation/curettage for unifocal bone disease to chemotherapy for multisystem involvement.